公开(公告)号：US20250034643A1

公开(公告)日：2025-01-30

申请号：US18717030

申请日：2022-12-13

Applicant: GENESPECTOR S.R.O.

Inventor： Ilona HROMADNIKOVA

IPC: C12Q1/6883

Abstract: Method of prediction of pregnancy complications, such as preeclampsia, fetal growth restriction, gestational hypertension, small for gestational age fetus, preterm birth, and also detection of chronic hypertension. Pregnant women are screened to determine the expression profile of one or more miRNAs in whole peripheral venous blood collected in the period of 10th-13th gestational week, whereas said one or more miRNAs are selected from the group miR-1-3p, miR-16-5p, miR-17-5p, miR-20a-5p, miR-20b-5p, miR-21-5p, miR-24-3p, miR-26a-5p, miR-92a-3p, miR-100-5p, miR-103a-3p, miR-126-3p, miR-130b-3p, miR-133a-3p, miR-143-3p, miR-145-5p, miR-146a-5p, miR-155-5p, miR-181a-5p, miR-195-5p, miR-210-3p, miR-221-3p, miR-342-3p, miR-499a-5p, and miR-574-3p.

公开(公告)号：US20240360507A1

公开(公告)日：2024-10-31

申请号：US18684929

申请日：2021-12-30

Applicant: GENESPECTOR S.R.O.

Inventor： Stanislav KMOCH ,  Lenka PIHEROVA ,  Hana HARTMANNOVA ,  Michal POHLUDKA ,  Martin RADINA

IPC: C12Q1/6876 ,  C12Q1/6851

CPC classification number: C12Q1/6876 ,  C12Q1/6851 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: Method for predicting a severity of an infectious disease and biomarker for use in carrying out the method and monitoring a therapy of an infectious disease using an RT-qPCR method, while the method is being performed on a nasopharyngeal swab sample determining the amount of serum amyloid A mRNA, preferably SAA1, and the amount of serum amyloid A mRNA is normalized to the amount of mRNA of a constitutively expressed gene, which is preferably UBC. Based on the determined normalized value of the amount of SAA1 mRNA in the sample, the severity of the course of an infectious disease, which may be of viral, bacterial, or fungal origin, is predicted, and the effectiveness of a therapy of the given disease is further monitored.

公开(公告)号：US20250110120A1

公开(公告)日：2025-04-03

申请号：US18833026

申请日：2022-01-31

Applicant: GENESPECTOR S.R.O. ,  WAKE FOREST UNIVERSITY HEALTH SCIENCES

Inventor： Stanislav KMOCH ,  Martina ZIVNA ,  Jan ZIVNY ,  Helena TRESLOVA ,  Anthony BLEYER ,  Kendrah KIDD

IPC: G01N33/543 ,  G01N33/68

Abstract: Method for determination of mutated form of mucin-1 protein in a biological sample comprising steps of adding biological sample to immobilized antibody against mutated form of VNTR MUC1fs, adding antibody against wild-type VNTR MUC1fs to portion of this mixture and performing quantitative analysis, wherein antibody against mutated form of VNTR MUC1fs is added to remainder of mixture of biological sample with immobilized antibody against mutated form of VNTR MUC1fs quantitative analysis is performed. Determination of concentration of MUC1fs in sample and determination of length of mutated or wild-type VNTR MUC1fs in sample is performed using appropriate calibration curves obtained by analyzing standard containing at least one epitope of mutated and at least one epitope of wild-type VNTR MUC1fs.